A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

NCT04252287 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

476

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: Canagliflozin 100 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC